About Wild Biotech

Develops a drug discovery platform that leverages a proprietary database of over 200 million microbial genes and machine learning to identify novel miniprotein and peptide therapeutics. This approach targets unmet clinical needs in immune and cardiometabolic disorders by discovering stable, orally administered scaffolds and advancing multiple candidates toward clinical development.

```xml <problem> Current drug discovery methods often struggle to identify novel therapeutic candidates, particularly for complex diseases like immune and cardiometabolic disorders. Traditional approaches may not fully leverage the potential of naturally occurring molecules and can be limited by challenges in oral bioavailability and stability. </problem> <solution> Wild employs a drug discovery platform that mines a proprietary database of over 200 million microbial genes to identify novel miniprotein and peptide therapeutics. The platform leverages machine learning to identify bioactive molecules and stable scaffolds suitable for oral administration. By mimicking evolutionary adaptations found in the animal kingdom, Wild aims to discover and develop innovative therapeutics that address unmet clinical needs in immune and cardiometabolic disorders. The platform includes a structural catalog of diverse miniproteins and peptides, including cyclic and knotted structures, enabling the discovery of molecules with unique therapeutic attributes. </solution> <features> - Wild DB: A database of over 200 million microbial genes sampled from diverse environments across six continents. - Proprietary structural catalog of highly diverse miniproteins and peptides, including cyclic and knotted structures. - Machine learning-powered mining of bioactive molecules. - Large-scale synthetic biology screening for hit validation. - Bioactivity testing and in-vivo characterization for lead optimization. - Focus on discovering stable scaffolds suitable for oral administration. - Identification of mimicry structures inspired by animal adaptations. </features> <target_audience> The primary target audience includes pharmaceutical companies seeking novel therapeutic candidates and strategic partnerships to expand their pipelines in immune and cardiometabolic disease areas. </target_audience> ```

What does Wild Biotech do?

Where is Wild Biotech located?

Wild Biotech is based in Boston, United States.

When was Wild Biotech founded?

Wild Biotech was founded in 2019.

How much funding has Wild Biotech raised?

Wild Biotech has raised $6.6M.

Who founded Wild Biotech?

Wild Biotech was founded by Neta Raab.

Neta Raab - CEO

Location

Boston, United States

Founded

2019

Funding

$6.6M

Employees

2 employees

Wild Biotech

Boston, United StatesFounded 20192700+ followers5/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.

Updated 3 months ago

Funding

$6.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Current drug discovery methods often struggle to identify novel therapeutic candidates, particularly for complex diseases like immune and cardiometabolic disorders. Traditional approaches may not fully leverage the potential of naturally occurring molecules and can be limited by challenges in oral bioavailability and stability.

Solution

Wild employs a drug discovery platform that mines a proprietary database of over 200 million microbial genes to identify novel miniprotein and peptide therapeutics. The platform leverages machine learning to identify bioactive molecules and stable scaffolds suitable for oral administration. By mimicking evolutionary adaptations found in the animal kingdom, Wild aims to discover and develop innovative therapeutics that address unmet clinical needs in immune and cardiometabolic disorders. The platform includes a structural catalog of diverse miniproteins and peptides, including cyclic and knotted structures, enabling the discovery of molecules with unique therapeutic attributes.

Target Audience

The primary target audience includes pharmaceutical companies seeking novel therapeutic candidates and strategic partnerships to expand their pipelines in immune and cardiometabolic disease areas.

Features

Wild DB: A database of over 200 million microbial genes sampled from diverse environments across six continents.
Proprietary structural catalog of highly diverse miniproteins and peptides, including cyclic and knotted structures.
Machine learning-powered mining of bioactive molecules.
Large-scale synthetic biology screening for hit validation.
Bioactivity testing and in-vivo characterization for lead optimization.
Focus on discovering stable scaffolds suitable for oral administration.
Identification of mimicry structures inspired by animal adaptations.